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ince the approval of the Pipeline embolization device (PED; Medtronic) by the US Food and Drug Administration in 2011, flow diversion has become a much more common and accepted treatment modality for both the originally intended large and giant cerebral aneurysms of the cavernous and paraclinoid internal carotid arteries and for aneurysms that would fall outside the initially approved indications.
Because of the prothrombotic nature of bare metal stents placed within the vasculature, thromboembolic events and in-stent thrombosis are significant risks associated with flow-diverting stents (FDSs). This necessitates the use of peri-and postprocedural dual antiplatelet therapy (APT). Current dosage recommendations are based primarily on the literature from cardiology and interventional radiology, with most studies utilizing a combination of 100-325 mg of aspirin and 75 mg of clopidogrel daily, beginning 7-10 days preoperatively. 1 Clopidogrel therapy typically continues for 3-6 months or more, while aspirin therapy is often continued indefinitely. Although dual APT has been shown to reduce the rate of thromboembolic events, it may also contribute to increased rates of complications.
Mitigating the risks of thromboembolic and hemorrhagic events is, therefore, of the utmost concern in the management of patients treated with FDSs. The use of platelet function testing (PFT) has been proposed as a possible solution to ensure an appropriate level of reduction in platelet activation and aggregation to minimize the risk of these adverse outcomes. Herein, we review the methodology, indications, and efficacy of PFT after flow diversion through a review of the most current medical literature.
Pharmacology of Platelet Adhesion and Antiplatelet Medications The Role of Platelets in Hemostasis
Under normal physiological conditions, thrombus formation begins when platelets adhere to exposed subendothelial collagen by binding von Willebrand factor at the site of vascular injury. Collagen-induced platelet activation causes platelets to de-granulate, releasing prothrombotic mediators, including adenosine diphosphate (ADP) and fibrinogen. 44 ADP released from platelets binds platelet receptors P2Y1 and P2Y12 and amplifies platelet response to other agonists, including thrombin; it also increases intracellular release of calcium, further potentiating platelet activation. 39 Collagen activation increases platelet production and release of thromboxane A 2 (TXA2), which activates platelet glycoprotein IIb/IIIa (GP-IIb/IIIa) receptors. Once activated, GP-IIb/IIIa receptors bind fibrinogen, leading to aggregation and plug formation through platelet-fibrinogen cross-linking. Once the primary platelet plug is formed, secondary hemostasis takes place via the coagulation cascade to stabilize the platelet plug though the formation of an insoluble fibrin clot.
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The invasive nature of endovascular procedures guarantees some level of increased platelet activation, and therefore increased risk of thrombosis, through this mechanism of endothelial damage and subendothelial matrix exposure. In the case of stenting and flow diversion procedures, this risk is further amplified by the introduction of bare metal devices into the vascular lumen. It has been demonstrated that platelet damage from shear forces as well as direct contact with the stent surface can cause platelet activation. 23, 25 For these reasons, FDS manufacturer recommendations and the standards of care dictate the use of dual APT before and after device implantation to reduce the risk of in-stent thrombosis and thromboembolic events.
Pharmacology of Antiplatelet Medications
Antiplatelet medications are favored for use in conjunction with FDSs for their ability to reduce platelet aggregation and thrombus formation, particularly in the arterial circulation, where anticoagulant agents are less effective. The most common dual APT regimen in use today is a combination of aspirin and clopidogrel. Aspirin, an irreversible COX-1 inhibitor, prevents the intraplatelet conversion of arachidonic acid to TXA2 for the life of the platelet. By decreasing the production and, therefore, the total amount of TXA2 released by platelets, activation of GP-IIb/IIIa receptors is reduced, resulting in decreased platelet aggregation.
Clopidogrel, an irreversible platelet P2Y12 receptor antagonist, prevents activation of the receptor by ADP. Reduced P2Y12 receptor activation leads to decreases in platelet aggregation, dense granule release, and GP-IIb/ IIIa activation. Clopidogrel, a prodrug, requires extensive metabolism by CYP enzymes, particularly CYP2C19. 44 For this reason, the levels of active metabolite can be affected by drug-drug interactions as well as genetic variability.
In instances in which clopidogrel is not used in dual APT or is believed to be ineffective, it is often replaced by another P2Y12 receptor antagonist, such as prasugrel or ticagrelor. Prasugrel, an irreversible P2Y12 inhibitor, also requires hepatic metabolism; however, prasugrel is more potent and appears to be less affected by genetic variations in P450 enzymes than clopidogrel. 20, 35 Ticagrelor is a reversible P2Y12 inhibitor that does not require hepatic metabolism, but, unlike clopidogrel and prasugrel, which directly bind and inhibit P2Y12 receptors, ticagrelor acts on an allosteric site to prevent ADP-induced conformational change of the receptor. 44 Triple APT, described in the cardiology literature, involves the addition of cilostazol, a selective inhibitor of phosphodiesterase III, to the standard dual APT regimen. This combination has been shown to be both effective and safe, with particular benefits noted in patients with diabetes. 2, 32 However, the use of 3 antiplatelet agents has not been described in the neurointerventional literature. In addition to modifications to the traditional aspirin and P2Y12 inhibitor combination, single-drug therapies such as the GP-IIb/IIIa inhibitors abciximab and tirofiban have been described. In the setting of PED, tirofiban has several proven benefits, including a good safety profile, reversibility in a matter of hours, cost effectiveness compared with other GP-IIb/IIIa inhibitors, and no need for PFT.
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Antiplatelet Drug Resistance
Determining the true rates of antiplatelet drug resistance in the general population is a difficult task, largely because of variations in testing methodologies and defining resistance. Reported rates of aspirin resistance have varied widely in PFT assays, but studies that have specifically measured levels of COX-1 acetylation or thromboxane B 2 in the blood have failed to detect significant rates of aspirin resistance in healthy individuals when compliance is ensured. 9, 21, 31, 41, 42 In studies on clopidogrel, resistance is most commonly defined as high on-treatment platelet reactivity to ADP by the P2Y12 receptor, indicating limited platelet inhibition. Given the variability of the PFT assays employed and their respective cut-off values for defining high on-treatment platelet reactivity, reported rates of clopidogrel resistance have varied from as low as 16% to as high as 50%. 33 Resistance to clopidogrel has been primarily attributed to genetic mutations and drug-drug interactions. Clopidogrel is a prodrug that must undergo extensive metabolism by the enteric and hepatic systems, including CYP enzymes. Genetic polymorphisms affecting these enzymes, particularly CYP2C19, have a significant impact on individual clopidogrel efficacy, as CYP2C19 is involved in both steps of the oxidative metabolism of clopidogrel. 6, 26, 29 Because of this reliance on CYP enzymes, it follows that drugs known to cause CYP inhibition can have similar effects on the metabolism of clopidogrel. Genetic mutations in the ABCB1 gene, which encodes a P-glycoprotein efflux pump involved in absorption of clopidogrel, have also been implicated in clopidogrel resistance, as has the concomitant use of drugs that interfere with these pumps, most notably proton pump inhibitors. 10 Prasugrel and ticagrelor are known to be more potent inhibitors of P2Y12 than clopidogrel, and multiple studies have demonstrated improved outcomes and greater overall response to these drugs compared with clopidogrel. 47, 48 Although this is certainly encouraging, there remains a small, but not insignificant, portion of the population in whom a therapeutic response to these drugs will fail to be achieved.
Platelet Function Testing
Using PFT to measure the extent of platelet inhibition in patients receiving APT has been considered a potential solution to the problem of clopidogrel resistance. Because each currently available test targets a specific pathway in the multistep process of platelet adhesion, activation, and aggregation, no single test has yet proven to be clearly superior, which may explain the large number of platelet function tests currently available. What follows is a brief, but by no means comprehensive, introduction to the most commonly used platelet function tests. These tests do, however, represent the overwhelming majority of those used in the currently available literature.
Light transmission aggregometry (LTA) is widely considered the gold-standard platelet function assay. LTA detects platelet aggregation after the addition of ADP to platelets by measuring the change in light transmittance. Despite its wide availability and good correlation between results and adverse events, it has limited reproducibility. Additionally, the process of centrifugation required to separate the platelets makes this test time consuming. 19 A similar test of platelet aggregometry is multiple electrode aggregometry, which detects platelet aggregation in whole blood after ADP-induced activation based on changes in electrical impedance. Advantages of multiple electrode aggregometry include its relative speed and the ability to use whole blood. 37 VerifyNow (Accumetrics) is a bedside assay that involves ADP stimulation of platelets in whole blood that bind to fibrinogen-coated polystyrene beads. As these platelet-bead complexes fall out of solution, the change in light transmittance is measured to assess the level of aggregation. This test has become increasingly popular as it is a fully automated bedside system that eliminates the need for experienced laboratory technicians. 27, 37 The platelet function analyzer (PFA-100) test attempts to mimic certain in vivo conditions. PFA-100 measures the time required for occlusion of the apparatus by platelet plugs under high shear rates while reproducing the pressure of the capillary in vivo. Activation of platelets is achieved by coating the walls of the membrane with collagen and ADP. 30 This test has the advantages of short processing time, use of whole blood, and the re-creation of in vivo thrombus formation. However, results are highly dependent on the level of von Willebrand factor present. Additionally, it has a low sensitivity for assessing the level of clopidogrel-induced inhibition, potentially reducing the clinical utility of this assay.
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The thromboelastography (TEG) hemostasis analyzer measures platelet-fibrin clot strength. Multiple protocols exist, but the methodology typically involves induction of platelet-fibrin clots by reptilase and Factor XIIIa, followed by the addition of ADP, to assess the contribution of the P2Y12 receptor to the clot formation process. 24 Although TEG tests multiple aspects of thrombus formation, as well as the interaction between platelets and the coagulation cascade, there remains a lack of standardization and a paucity of studies available to assess the predictive value of adverse effects based on TEG. 5, 15 PFT in the Neurosurgical and Neurointerventional Literature Studies Supporting the Use of PFT Studies examining antiplatelet use during stent-assisted coiling of intracranial aneurysms have suggested that the degree of platelet inhibition is related to the development of ischemic lesions on follow-up MRI scans. 49 Likewise, studies supporting the use of PFT cite results indicating that hypo-or hyperresponse to clopidogrel is associated with increased rates of complications in patients after PED placement (Table 1 ). In 2013, Delgado Almandoz et al. 16 published the results of a retrospective, single-center study of 44 patients undergoing PED placement with the goal of identifying optimal preprocedure P2Y12 reaction unit (PRU) values as reported by VerifyNow testing. Most patients were started on a standard dual APT regimen of aspirin and clopidogrel 10 days before the procedure, and PFT was carried out the day before the scheduled procedure, with a target PRU range of 80-200. Clopidogrel hyporesponders (PRU > 200) were switched to prasugrel, whereas hyperresponders (PRU < 80) received clopidogrel doses at increasing intervals until target PRU values were achieved. In this cohort, all 4 of the major perioperative thromboembolic and hemorrhagic complications following PED placement occurred in patients determined to be hyporesponsive to clopidogrel (PRU > 200), all of whom then received either changes to their dose or alternative P2Y12 antagonists. Based on this cohort, the strongest independent predictor of all and major perioperative thromboembolic and hemorrhagic complications after PED placement was a preprocedure PRU value of < 60 or > 240.
The following year, Delgado Almandoz et al. 17 reported findings from another retrospective, single-center study of 100 patients undergoing endovascular treatment of unruptured cerebral aneurysms-including but not limited to PED placement-with a goal of assessing the extent of variability in patient response to clopidogrel and the frequency of "delayed conversion" to a hyperresponse to clopidogrel. They performed PFT using VerifyNow and set a target PRU range of 60-240. Using extensive followup testing, they found a significant decrease in mean PRU values with continued administration of a standard 75-mg daily clopidogrel dose. After 8-9 doses, there was a mean PRU of 137, whereas after 30 doses, the same cohort demonstrated a mean PRU of 59. The authors also found that 59% of patients who were not initially considered hyperresponders experienced a delayed conversion to hyperresponsiveness in follow-up testing. Additionally, a hyperresponse to clopidogrel was associated with a significantly higher risk of a major hemorrhagic event than was observed in those who did not exhibit hyperresponse (11% vs 0%). Conversely, a hyporesponse to clopidogrel was as-sociated with a significantly increased risk of thromboembolic events compared with patients who did not demonstrate a hyporesponse (60% vs 3.6%).
In 2015, Tan et al. 46 reported on a retrospective, singlecenter study of 74 patients who underwent PED placement, with a goal of identifying risk factors for thromboembolic events. Using VerifyNow and a target preprocedural PRU of < 230, patients in whom there was no response to clopidogrel were given an additional 600-mg dose of clopidogrel immediately after the procedure, but no procedures were delayed to achieve the target PRU. There was an observed trend toward increased thromboembolic events in those patients with a preprocedural PRU of > 208, but this trend was not statistically significant.
Oran et al. 36 performed a retrospective, single-center study of 100 consecutive patients treated with PED. Patients were divided into 2 groups: one group received tailored therapy based on PFT by multiple electrode aggregometry (Multiplate analyzer), while the other group did not undergo PFT and received no tailored therapy. Clopidogrel nonresponse was set at an area under the curve of > 468. Treatment was tailored in this group with one of 3 alterations to the standard dual APT: ticlopidine, ticlopidine along with bridging intravenous tirofiban, or increased intraoperative intravenous heparin with no change in APT. Of the complications assessed in the 2 groups (thrombotic, hemorrhagic, and technical), the tailored therapy group that received PFT had significantly fewer thrombotic complications (0 vs 3). Of note, the 2 groups considered in this study were separated by a fixed point in time-untested patients earlier, followed by the group that received the PFT and tailored therapy-so the possibility remains that improved outcomes in the latter group were due to increased surgical experience.
McTaggart et al. 34 performed a prospective, single-center study examining the use of TEG to measure platelet reactivity in 31 patients undergoing PED placement. All patients were started on a standard dual APT regimen of 75 mg of clopidogrel and either 325 mg or 81 mg of aspirin daily for at least 7 days before the procedure. All patients were tested by TEG either before or on the day of the procedure, and a target therapeutic range of 30%-0% ADP-induced inhibition was set. Patients who were hyporesponsive (ADP-induced platelet inhibition of < 30%) either received an additional preprocedural loading dose of 600 mg of clopidogrel or they were transitioned to prasugrel with or without antiplatelet bridging via the GP-IIb/ IIIa antagonist Integrelin, depending on the proximity to the procedure. TEG testing resulted in APT modification in 12 patients (35%), 11 of whom were found to be hyporesponders. Within the entire cohort, there were no hemorrhagic complications or new permanent neurological deficits, but there were still minor thromboembolic events in 3 patients and suspected transient ischemic attacks in 5 others. Among these patients who experienced thromboembolic or ischemic events, 75% were found to be clopidogrel hyporesponsive by TEG testing, with a cutoff of ADP-induced platelet response of < 30%.
In 2016, Raychev et al. 40 reported on a retrospective, single-center study to determine the strongest predictors of thrombotic and hemorrhagic complications associated with these procedures. Unique to this study, LTA was used as a noncommercial PFT to assess clopidogrelinduced ADP% inhibition in 45 patients undergoing PED procedures. Although procedural duration as measured by fluoroscopy time was shown to have the greatest impact, ADP% inhibition of > 50% was also shown to have a significant association with thrombotic complications.
Studies Critical or Unsupportive of the Use of PFT
Conversely, studies demonstrating that routine PFT is unjustified identify substantial variability in PFT application and potential morbidity related to the use (Table 1) . In 2013, separate commentaries by Chandra 12 and Comin and Kallmes 14 were published that both argued that, based on the available literature, particularly the large, randomized, controlled trials in the cardiology literature, routine PFT in the neurointerventional setting was unjustified. The following year, on behalf of the Society of Neurointerventional Surgery Standards and Guidelines Committee, Gandhi et al. 22 produced a comprehensive review of the available cardiology and neurointerventional literature regarding APT and PFT to assess how these should be applied in the neurointerventional setting. Most of the evidence reviewed was Level B or Level C, including singlecenter randomized trials, nonrandomized studies, expert opinion, and case studies. The authors concluded that while the available cardiology and neurointerventional literature agreed that sub-and supratherapeutic platelet inhibition were associated with increased risk of thromboembolic and hemorrhagic complications, respectively, there was insufficient evidence to justify a recommendation of routine PFT before neurointerventional procedures.
Faught et al. 18 published the results of a multicenter survey examining neuroendovascular practices in the United States related to the use of APT and PFT. They received 74 responses, 56.8% of which were from academic institutions. The results demonstrated significant heterogeneity in the practice patterns of neurointerventional surgeons regarding the type of APT used, dosing, perioperative duration, and use of PFT. The authors also proposed several potential explanations for this heterogeneity, including the increasing number of new antiplatelet medications entering the market and controversy within the literature surrounding the efficacy of PFT.
In 2015, Flechtenmacher et al. 20 reported on a prospective, single-center study examining the correlation between clopidogrel-induced platelet inhibition measured by 3 popular PFT methods and the association of reported clopidogrel resistance with actual thromboembolic events. One hundred seven consecutive patients undergoing intraor extracranial stent placement or stent-assisted coiling of intracranial aneurysms were tested with all 3 methods being studied: LTA, VerifyNow, and Multiplate analyzer. All patients received a standard dual APT regimen consisting of 100 mg of aspirin and 75 mg of clopidogrel daily or they were given 600 mg of clopidogrel the day before the procedure. If any 2 or all 3 of the tests indicated hyporesponsiveness to clopidogrel, the dose was increased to 150 mg daily. Sixty-seven percent of the patients in the cohort were hyporesponsive to clopidogrel according to at least one test method, and 23% were hyporesponsive according to all 3 tests. LTA testing was the most sensitive method (77.8%) by which to predict thromboembolic complications, followed by VerifyNow (66.7%) and Multiplate analyzer (44.4%). The authors noted the complication rate of patients deemed hyporesponsive to clopidogrel by LTA was 14.3%, compared with just 3.7% in patients determined to be responsive. Although LTA testing showed more promise than the other 2 PFT methods in this study, the differences reported failed to reach statistical significance.
Also in 2015, Brinjikji et al. 8 used the International Retrospective Study of Pipeline Embolization Device registry to compare outcomes between patients receiving PFT and patients who did not have PFT prior to PED placement. They found that, even when differences in baseline characteristics like age, aneurysm size, and number of PEDs placed were controlled, patients receiving PFT experienced significantly higher rates of intracranial hemorrhage and neurological morbidity. Unfortunately, the database used did not provide any insight into why these patients received PFT. There are many other limitations to this study, including variable APT regimens, a lack of information about patient comorbidities, and a lack of information on what, if any, changes to therapy were made in response to PFT.
In 2016, Skukalek et al. 45 published an extensive review and meta-analysis examining the impact of APT and PFT in patients treated with PED on the rates of thrombotic and hemorrhagic complications. Their analysis of 19 single-center and multicenter studies found no significant association between the use of PFT and the rates of symptomatic thrombotic or hemorrhagic complications with PED placement. Of these 19 studies, only 6 involved the consistent use of PFT, with a mix of VerifyNow, Multiplate, and platelet inhibition assays.
PFT in the Cardiology Literature
Compared with the neurosurgical and neurointerventional literature, the cardiology literature regarding APT and PFT is far more robust and includes several large, randomized, controlled trials (Table 2 ). One such study is the Gauging Responsiveness with A VerifyNow AssayImpact on Thrombosis and Safety (GRAVITAS) trial, 38 a multicenter, randomized, double-blind, active-control trial that compared the use of high-dose (600-mg loading dose, 150 mg daily) and standard-dose (75 mg daily with no loading dose) clopidogrel treatment in patients with high on-treatment platelet reactivity following percutaneous coronary intervention. The GRAVITAS trial concluded that there was no significant difference between the standard-and high-dose clopidogrel groups in terms of reducing the incidence of the primary end points of death within 6 months by cardiovascular disease, nonfatal myocardial infarction, or stent thrombosis. Although high-dose clopidogrel was not shown to decrease morbidity and mortality rates compared with the standard dose, neither was it found to cause a significant increase in intracranial hemorrhage or moderate to severe bleeding events. The GRAVITAS trial was followed by another landmark randomized, controlled trial known as ARCTIC (The Assessment by a Double Randomization of a Conventional Antiplatelet Strategy versus a Monitoring-guided Strategy for Drug-Eluting Stent Implantation and of Treatment Interruption versus Continuation One Year after Stenting).
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A total of 2440 lower-risk patients were randomized to receive platelet function monitoring with subsequent drug adjustments in those with a documented poor response to APT or conventional therapy without monitoring and medication adjustments. There was no statistically significant difference between the 2 treatment arms in regard to their primary outcomes (composite of death of any cause, myocardial infarction, stent thrombosis, stroke, or urgent revascularization within 1 year after initial treatment) or secondary outcomes (composite of stent thrombosis or urgent revascularization). Additionally, there was no difference in the rate of major bleeding events between the treatment arms. It is important to consider, however, that this was designed as a randomization of treatment strategy in lower-risk patients rather than a comparison of responders to platelet therapy versus nonresponders.
The following year, Janssen and ten Berg 28 performed an extensive review of the literature to assess the efficacy of tailored APT with the use of PFT in stable patients undergoing percutaneous coronary intervention. They found no observable benefit from adjusting the antiplatelet regimen in this group when increasing clopidogrel dosage or adjunctive use of GP-IIb/IIIa inhibitors to correct for high on-treatment platelet reactivity. They also examined the potential use of more potent P2Y12 inhibitors in this group, such as prasugrel or ticagrelor, but concluded that the increased bleeding risk associated with these drugs might outweigh any potential improvement in the already low rates of thrombotic complications found in these patients.
A meta-analysis of randomized trials in the cardiology literature performed by Aradi et al. 4 in 2013, however, indicated that platelet response testing and medication adjustments reduced the rates of thrombotic events during percutaneous coronary interventions compared with nontesting. There was no significant increase in major bleeding in the testing and nontesting cohorts. A meta-regression analysis indicated that the benefits of PFT were dependent on the patient's inherent risk of stent thrombosis, suggesting that testing might be better used in a subgroup of patients at elevated risk for thrombosis-related complications.
After a careful review of the available evidence, The Study Group on Biomarkers in Cardiology of the Acute Cardiovascular Care Associations of the European Society of Cardiology and the Working Group on Thrombosis of the European Society of Cardiology published a position statement in 2015 stating that there was no evidence that testing and modifying the antiplatelet regimen before percutaneous coronary interventions leads to improvements in outcomes. 3 However, their recommendations were based on the use of prasugrel or ticagrelor as firstline agents rather than clopidogrel. For selected patients on clopidogrel, the utility of PFT in guiding therapy was uncertain.
Conclusions
PFT is an area of considerable controversy in both the neurointerventional and interventional cardiology realms. Our practice with flow diversion is derived predominantly from the initial trials with the PED (e.g., the PUFS trial) and the interventional cardiology literature, because there is insufficient evidence in the neurointerventional literature to recommend a standard strategy regarding PFT. Likewise, cardiology has been an early adopter of secondgeneration antiplatelet agents (prasugrel and ticagrelor), whereas most of the neurointerventional literature continues to focus on clopidogrel. Those of us who routinely use flow diversion as a treatment for cerebral aneurysms will continue to look toward the interventional cardiology literature for guidance to our future practice.
